DIABLO (Direct IAP-Binding Protein with Low pI), also known as SMAC (Second Mitochondria-Derived Activator of Caspases), is a mitochondrial protein that plays a critical role in regulating apoptosis through its interactions with Inhibitor of Apoptosis Proteins (IAPs). First characterized in 2000 by Du et al., SMAC/DIABLO is released from the mitochondrial intermembrane space during the early stages of programmed cell death, where it functions as a potent pro-apoptotic molecule by neutralizing IAP-mediated caspase inhibition [1].
In the context of neurodegenerative diseases, SMAC/DIABLO has emerged as a key player in the death of neurons in both Alzheimer's disease and Parkinson's disease. The protein's dual role—as both a mediator of pathological cell death and a potential therapeutic target—has made it the subject of extensive research over the past two decades [2].
| Second Mitochondria-Derived Activator of Caspases (SMAC) | |
|---|---|
| Gene Symbol | DIABLO |
| Full Name | Direct IAP-Binding Protein with Low pI |
| Chromosome | 12q24.31 |
| NCBI Gene ID | [56616](https://www.ncbi.nlm.nih.gov/gene/56616) |
| OMIM | 604476 |
| Ensembl ID | ENSG00000140297 |
| UniProt ID | [Q9NR28](https://www.uniprot.org/uniprot/Q9NR28) |
| Protein Length | 239 amino acids |
| Cellular Location | Mitochondria (intermembrane space) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer |
The DIABLO gene spans approximately 5.5 kb on chromosome 12q24.31 and consists of 6 exons encoding a 239-amino-acid precursor protein. The gene is evolutionarily conserved across vertebrates, with orthologs identified in mice, rats, zebrafish, and other model organisms. The N-terminal 55 amino acids encode a mitochondrial targeting sequence (MTS) that directs the protein to the mitochondrial intermembrane space, followed by a functional domain that binds IAP proteins.
Phylogenetic analysis reveals that DIABLO belongs to a family of mitochondrial pro-apoptotic proteins that includes OMI/HtrA2, which shares functional similarity in its ability to neutralize IAPs. However, DIABLO and OMI/HtrA2 differ in their mechanism of release from mitochondria and their specific IAP binding profiles.
SMAC/DIABLO is synthesized as a 239-amino-acid precursor with an N-terminal mitochondrial targeting sequence (residues 1-55) that is cleaved upon import into the mitochondrial intermembrane space, generating the mature 184-amino-acid active form [1:1]. The mature protein forms a homodimer, with each monomer adopting an extended barrel-like structure. The critical IAP-binding motif is located at the N-terminus (residues 56-59: Ala-Val-Pro-Ile in the mature protein), which mimics the IBM (IAP-binding motif) found in other pro-apoptotic proteins.
The dimeric structure of SMAC/DIABLO is essential for its function, as the dimer interface creates a binding surface that engages multiple BIR (baculovirus IAP repeat) domains simultaneously, providing high-affinity interaction with IAP proteins such as XIAP, cIAP1, and cIAP2.
The primary function of SMAC/DIABLO is to promote caspase activation by antagonizing IAP proteins. Under normal cellular conditions, SMAC/DIABLO resides in the mitochondrial intermembrane space and has no pro-apoptotic activity. However, upontriggering of the intrinsic (mitochondrial) apoptosis pathway, SMAC/DIABLO is released into the cytosol through the mitochondrial outer membrane permeabilization (MOMP) channel [1:2].
Once in the cytosol, SMAC/DIABLO binds to IAP proteins through its N-terminal IBM motif, displacing caspases from IAP-mediated inhibition. The key targets include:
By neutralizing these IAPs, SMAC/DIABLO removes the brake on caspase activation and enables efficient execution of apoptosis [3].
SMAC/DIABLO operates in parallel with cytochrome c in the apoptotic cascade. Both are released from mitochondria upon MOMP, but they target different components of the apoptotic machinery:
This dual mechanism ensures robust activation of the caspase cascade and efficient cell death.
SMAC/DIABLO is expressed in most human tissues, with highest expression in testis, heart, brain, and skeletal muscle. In the brain, expression is detected in both neurons and glia, with particular abundance in the hippocampus, cortex, and basal ganglia—regions affected in neurodegenerative diseases.
The DIABLO gene is transcriptionally regulated by several factors:
SMAC/DIABLO activity is regulated at multiple levels:
Alzheimer's disease (AD) is characterized by progressive neuronal loss in the hippocampus and cortex, with apoptosis being a major mechanism of neuronal death. SMAC/DIABLO has been implicated in multiple aspects of AD pathogenesis.
In AD, accumulation of amyloid-beta (Aβ) peptides triggers mitochondrial dysfunction and promotes SMAC/DIABLO release from mitochondria. Studies have demonstrated that Aβ treatment of neurons leads to rapid release of SMAC/DIABLO into the cytosol, preceding caspase activation and cell death [4].
The mechanism involves:
Recent research has revealed a connection between SMAC/DIABLO and tau pathology in AD. Tau pathology promotes mitochondrial dysfunction and enhances SMAC/DIABLO release, while SMAC/DIABLO can in turn accelerate tau phosphorylation through caspase-dependent pathways [6].
The SMAC/IAP axis represents a promising therapeutic target in AD:
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra. Mitochondrial dysfunction is a central feature of PD pathogenesis, and SMAC/DIABLO plays a critical role in dopaminergic neuron death.
Multiple genetic and environmental factors linked to PD affect mitochondrial function:
SMAC/DIABLO release is increased in dopaminergic neurons under these conditions, promoting caspase activation and cell death [8].
The aggregation of alpha-synuclein (α-syn), a hallmark of PD, is linked to mitochondrial dysfunction and SMAC/DIABLO release. α-syn can:
Targeting the SMAC/IAP pathway in PD offers several therapeutic opportunities:
SMAC/DIABLO has been implicated in motor neuron death in ALS. Mutations in SOD1, TDP-43, and C9orf72 repeat expansions all lead to mitochondrial dysfunction and enhanced SMAC/DIABLO release. Studies in ALS models show that:
In Huntington's disease (HD), mutant huntingtin protein promotes mitochondrial dysfunction and SMAC/DIABLO release. The SMAC/IAP pathway contributes to the selective vulnerability of striatal neurons in HD.
Although primarily an autoimmune demyelinating disease, axonal loss in MS involves apoptotic mechanisms with SMAC/DIABLO playing a role in neuronal degeneration.
Neuroinflammation is a common feature of neurodegenerative diseases, and SMAC/DIABLO has been implicated in the inflammatory response [10]:
The Inhibitor of Apoptosis Proteins (IAPs) are a family of anti-apoptotic proteins that play crucial roles in neuronal survival. The major neuronal IAPs include:
| IAP | Gene | Function in Neurons |
|---|---|---|
| XIAP | XIAP | Inhibits caspases 3, 7, 9; highly expressed in neurons |
| cIAP1 | BIRC2 | Regulates NF-κB signaling; protects against TNF-α toxicity |
| cIAP2 | BIRC3 | Similar to cIAP1; role in microglial survival |
| Survivin | BIRC5 | Cell cycle regulation; low in mature neurons |
The balance between pro-apoptotic molecules (like SMAC/DIABLO) and IAPs determines neuronal fate. In neurodegenerative diseases, this balance shifts toward apoptosis due to increased SMAC/DIABLO release and/or decreased IAP function [11].
SMAC mimetics (also called IAP antagonists) are small molecules that mimic the IAP-binding function of SMAC/DIABLO. Several generations have been developed:
In neurodegenerative disease models, SMAC mimetics have shown complex effects—sometimes protective, sometimes detrimental—depending on the context and disease stage.
Therapeutic targeting of the SMAC/IAP axis in neurodegeneration presents challenges:
Recent research suggests that low-dose SMAC mimetics or selective modulation of specific IAPs may provide neuroprotective effects without promoting excessive cell death [13].
The release of SMAC/DIABLO from mitochondria is closely linked to mitochondrial quality control mechanisms. Mitophagy—the selective autophagy of damaged mitochondria—can prevent SMAC/DIABLO release by eliminating compromised mitochondria before MOMP occurs [14].
In neurodegenerative diseases, mitophagy is often impaired, leading to accumulation of dysfunctional mitochondria that are more prone to release SMAC/DIABLO. Key regulators include:
Enhancing mitophagy may represent a strategy to prevent SMAC/DIABLO release and subsequent neuronal death.
While apoptosis is the primary cell death pathway influenced by SMAC/DIABLO, it can also intersect with other cell death modalities:
SMAC/DIABLO and its fragments have potential as biomarkers in neurodegenerative diseases:
Several animal models have been used to study SMAC/DIABLO in neurodegeneration:
Research on SMAC/DIABLO in neurodegeneration continues to evolve:
Du C, et al. (2000). SMAC/DIABLO release from mitochondria into cytosol. Nat Cell Biol 2: 489-497. 2000. ↩︎ ↩︎ ↩︎
Martinez-Ruiz G, et al. (2005). Role of SMAC/DIABLO in neurodegeneration. Cell Death Differ 12: 1006-1014. 2005. ↩︎
Fulda S, et al. (2002). IAP antagonists: smart drugs for cancer therapy. Nat Rev Cancer 2: 579-593. 2002. ↩︎
Gates K, et al. (2008). SMAC activation in Alzheimer disease. J Neurosci 28: 11488-11499. 2008. ↩︎
Wei MC, et al. (2008). Proapoptotic BAX and BAK in Alzheimer disease. Nat Med 14: 837-848. 2008. ↩︎
Wang J, et al. (2024). SMAC and tau pathology in AD. Acta Neuropathol 147: 345-359. 2024. ↩︎
Moran J, et al. (2010). SMAC mimetics in Alzheimer disease models. Cell Death Differ 17: 738-748. 2010. ↩︎
Ok H, et al. (2013). Mitochondrial dysfunction in Parkinson disease. Nat Rev Neurosci 14: 265-281. 2013. ↩︎
Burke R, et al. (2017). SMAC release in dopaminergic neurons. Mol Cell Neurosci 84: 1-11. 2017. ↩︎
Zhang Y, et al. (2020). SMAC and neuroinflammation. J Neuroinflammation 17: 234. 2020. ↩︎
Chen L, et al. (2019). IAP proteins in neuronal survival. Trends in Neurosciences 42: 544-556. 2019. ↩︎
Yang H, et al. (2022). Therapeutic targeting of SMAC pathway. Pharmacol Rev 74: 567-602. 2022. ↩︎
Park S, et al. (2023). SMAC-based therapeutics in neurodegenerative diseases. Nat Rev Drug Discov 22: 455-472. 2023. ↩︎
Liu X, et al. (2021). Mitochondrial quality control in neurodegeneration. Autophagy 17: 1757-1773. 2021. ↩︎